Top Back to top

Observational study on the use of B cell receptor kinase inhibitors and BCL2 antagonists prior to allogeneic hematopoietic stem cell transplantation for B cell malignancies: A joint project of the EBMT Lymphoma and Chronic Malignancy Working Parties.

Chronic Malignancies Working Party (CMWP)
Lymphoma Working Party (LWP)
Study number:
2013-N-02
Type of transplant:
 
Short title:
BCRi survey
Study status:
 
Deadline for data collection:
 
Study design:
 
Primary objective:
OBJECTIVE: To assess safety and efficacy of HSCT after previous exposure to BCRi/BCL2a
Key inclusion criteria:
First allogeneic HSCT, diagnosis of MCL, CLL, FL, WM or DLBCL, age over 18 years at transplant, allografted 2013-March 2015, donor SIB or well or partially matched unrelated, any conditioning regimen, documented pre-transplant exposure to BCRi/BCL2a
Country:
 
Principal investigator:
Peter Dreger, Johannes Schetelig
Principal investigator email:
 
EBMT Study coordinator:
Hervé Finel